Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 883-890

  Roselli, Mario ^a   Guadagni, Fiorella ^b   Buonomo, Oreste ^a   Belardi, Augusto ^a   Vittorini, Vincenzo ^a   Cavazzana, Andrea ^a   Spagnoli, Luigi Giusto ^a   Cipriani, Cesidio ^c   Casciani, Carlo Umberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

125I FO23C5; Anti CEA MAb; Carcinoembryonic antigen; Colorectal cancer; Radioimmunoguided surgery

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TUMOR LOCALIZATION;

AGED; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; INTRAOPERATIVE PERIOD; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOIMMUNODETECTION; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029898693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Heald RJ, Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 2: 1474-82, 1986.
2. 111In-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 46: 6494-502, 1986.
3. Colcher D, Esteban J, Carrasquillo JA: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218-24, 1987.
4. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 185: 179-186, 1992.
5. Carrasquillo JA, Sugarbaker P, Colcher D, et al: Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody. Radiology 167: 35-40, 1988.
6. Meredith RF, Bueschen AJ, Khazaeli MB, et al: Treatment of metastatic prostate carcinoma with radiolabelcd antibody CC49. J Nucl Med 35: 1017-22, 1994.
7. Roselli M, Casciani CU, Guadagni F, et al: Monoclonal Antibodies in the Management of Carcinoma Patients. Med Oncol & Tumor Pharmacother 8: 223-228, 1991.
8. Roselli M, Guadagni F, Buonomo O, et al: Clinical value of radiolabeled monoclonal antibodies in the management of carcinoma patients. In Vivo 7(6B): 615-622, 1993.
9. Aitken DR, Thurston MO, Hinkle GH, et al: Portable gamma detecting probe for radioimmunolocalization of experimental colon tumor xenografts. J Surg Res 36: 480-9, 1984.
10. Martin EW, Hinkle GH, Tuttle S: Intraoperative radioimmunodetection of colorectal tumors with a hand held radiation detector. Am J Surg 150; 672-75, 1985.
11. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, et al: Radioimmunoguided surgery using the monoclonal antibody B 72.3 in colorectal tumors. Dis Colon Rectum 30: 761-764, 1987.
12. Martin E.W., Tuttle S.E., Rousseau M., et al: Radioimmunoguided surgery: intraoperative use of monoclonal antibody 17.1A in colorectal cancer. Hybridoma 5: s97-s108, 1986.
13. Hinkle G, Mojzisik CM, Loesch JA, et al: The evolution of the Radioimmunoguided Surgery System: An Innovation Technique for the Intraoperative Detection of Tumor. Antibody Immunocon Radiopharm 4: 339-358, 1 991.
14. Badellino F, Percivale P, Meszaros P, et al: Perioperative Radioimmunolocalization of Colorectal Cancer by Radiolabeled Monoclonal Antibodies. J Surg Oncol 2: 86-91, 1991.
15. Nieroda C, Mojzisik C, Sardi A, et al: The Impact Of Radioimmunoguided Surgery (RIGS) on Surgical Decision Making in Colorectal Cancer. Dis Colon Rectum 32: 927-932, 1989
16. Di Carlo V, Badellino F, Stella M, et al: Role of B72.3 iodine-125-labeled monoclonal antibody in colorectal cancer detection by radioimmunoguided surgery. Surgery 1 15: 190-8, 1994.
17. Dawson PM, Blair SD, Begent RHJ, Kelly AMB, Boxer GM, Theodorou NA: The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer. Dis Colon Rectum 34: 217-22, 1991.
18. Arnold MW, Schneebaum S, Berens A, Mojzisik C, Hinkle G, Martin EW: Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 112: 624-30, 1992.
19. Minton JP, Hoehn JL, Gerber DM: Results of a 400 patients second look surgery colorectal cancer study. Cancer 55: 1284-90, 1985.
20. Martin EW, Minton JP, Carey LC: CEA directed second look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 202: 310-7, 1985.
21. Sardi A, Agnone CM, Nieroda C, et al: Radioimmunoguided Surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examinations. South Medical Journal 82: 1235-1244, 1989.
22. Guadagni F, Roselli M, Amato T, et al: Tumor-associated glycoprotein-72 (TAG-72) serum levels complement carcino-embryonic antigen (CEA) levels in monitoring patients with gastrointestinal carcinoma: A longitudinal study. Cancer 68: 2443-2450, 1991.
23. Guadagni F, Roselli M, Cosimelli M, et al: TAG-72 (CA 72-4 Assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 72 (7): 2098-2106, 1993.
24. Guadagni F, Roselli M, Cosimelli M, et al: Quantitative analysis of CEA in tissues of primary colorectal (CR) carcinoma patients. Cancer Res (Proceedings) 35: pp. 15(86), 1994.
25. 2 Fragments of an anti-carcinoembryonic antigen monoclonal antiboby: A multicenter study. Cancer Res 49: 3095-3103, 1989.
26. Roselli M, Guadagni F, Buonomo O, Vittorini V, Belardi A, Casciani CU: New strategies for the optimization of radioimmunoguided surgery. Annual Meeting CNR, Rome, Italy. Abs Book pp.255, 1994.
27. Paganelli G, Stella M, Zito F, et al: Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J Nucl Med 35: 1970-1975, 1994.
28. Colcher D, Bird R, Roselli M, et al: In vivo tumor targeting of a recombinant single-chain antigen bonding protein. J Natl Cancer Inst 82: 1991-97, 1990.
29. Carrasquillo JA, Sugarbaker P, Colcher D, et al: Radioimmunoscintigraphy of colon cancer with I-131-labeled B72.3 monoclonal antibody. J Nucl Med 29: 1022-28, 1988.
30. Oredipe OA, Barth RF, Tuttle SE, et al: Limits of sensitivity for the radioimmunodetection of colon cancer by means of a hand held gamma probe. Nucl Med Biol 15: 595-603, 1988.
31. Arnold M, Schneebaum S, Berens A, et al: Intraoperative Detection of Colorectal Cancer With Radioimmunoguided Surgery and CC49, Second-generation Monoclonal Antibody. Ann Surg 216: 627-32, 1992.
32. Goldenberg DM, Goldenberg H, Sharkey RM, et al: Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123-1 or 99mTc. Cancer Res50(3s): 909s-921s, 1990.
33. Rowlinson G, Paganelli G, Snook D, Epenetos M: Radiolocalization of an anti-CEA monoclonal antibody (FO23C5) and its fragments in a colon carcinoma xenograft model. Int J Biol Markers 3: 259-264, 1988.
34. 131I-CC49 and IFN-γ. Dis Col Rectum 37(2): s100-s105, 1994.
35. Kuhn JA, Beatty BG, Wong JVC, et al: Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 51: 2335-9, 1991.
36. 131I-CC49) when given in combination with IFN-γ. Cancer Res 53: 600-8, 1993.
37. Guadagni F, Roselli M, Nieroda C, Dansky Ullmann C, Schlom J, Greiner JW: Biological response modifiers as adjuvants in monoclonal antibody-based treatment. In Vivo 7: 591-600, 1993.